Is uterine leiomyoma associated with a polymorphism in the interleukin 1-beta gene?
The IL-1beta-511 promoter polymorphism is related to an increased susceptibility to uterine leiomyoma, suggesting that this polymorphism does contribute to the development of this disease.
Tenecteplase is quicker to prepare than standard therapy, resulting in a significant improvement in performance against the national service framework target.